Identify, confirm, and prioritize novel therapeutic targets and biomarkers using our data-driven bioinformatics and screening platforms. We streamline MoA discovery and reduce late-stage risks

Advance your monoclonal antibodies (mAbs), bispecifics, and ADCs using our comprehensive in vitro and in vivo platforms. We provide systems for efficacy, safety, and deep mechanistic insight.

Screen your compounds efficiently across our vast cell line collection using platforms like OmniScreen and OrganoidXplore for high-throughput, translational results.

Assess anti-tumor potency using world-leading models (PDX, Syngeneic, Organoid) and advanced platforms like MuScreen for robust, predictive preclinical data.

Characterize drug-target interactions and confirm the Mechanism of Action (MoA) for your therapeutic candidate through integrated in vitro and in vivo studies.

Leverage computational analysis and our 'omics' expertise to integrate complex data, optimize study design, and make better-informed, data-driven decisions faster.

Screen your compounds efficiently across our vast cell line collection using platforms like OmniScreen and OrganoidXplore for high-throughput, translational results.